Johnson & Johnson's CEO highlights America's leading role in biopharmaceutical innovation, with U.S. companies driving 55% of global R&D and launching most new medicines. Artificial intelligence is accelerating drug discovery and clinical trials, while also enhancing clinical judgment and surgical precision. The company is investing over $55 billion in U.S. research and manufacturing over the next four years to maintain this leadership and ensure accessibility of treatments. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT AI is accelerating drug discovery and clinical trials, and enhancing clinical judgment and surgical precision in healthcare.
RANK_REASON This is a commentary piece from a CEO discussing industry trends and company investment, not a direct release of a new product or research.
